Greg led the efforts to build the Genece team and establish our partnership with GC Genome to bring their novel early cancer detection technology to the US. Greg has a long track record of developing and commercializing novel molecular diagnostics technologies and instrumentation for clinical labs. Greg was formerly a founder at ChromaCode, taking the company from inception to profitability as it’s CEO. He also guided four-fold revenue growth as the GM of commercial operations at Luminex and previously held commercial leadership roles at Nanogen, Chiron, and BioRad. Greg has a degree in molecular and cellular biology from the University of Colorado Boulder and dual MBA and MHA degrees from the University of Minnesota.

Kristin leads external scientific engagement and communication along with strategic marketing. Dr Fathe has a decade of experience in the diagnostics industry focusing on understanding how new diagnostic tools can best fill unmet customer needs. Most recently, she was Sr Director of Scientific Affairs at ChromaCode and before that held roles at Luminex, a Diasorin company, and served as laboratory manager and journal editorial assistant at the University of Texas Austin. Dr Fathe holds a BS in biochemistry and molecular biology from Trinity University and a PhD from the University of Texas Austin Dell Pediatric Research Institute.

Andrew leads the team responsible for the algorithmic and bioinformatic components of the Genece technology. Dr Carson has over a decade of experience in the diagnostics industry leveraging his training in cancer research and bioinformatics. Before joining Genece, he was Senior Director of Bioinformatics at Cradle Genomics and the Director of Informatics at Invivoscribe. Andrew received his BS in Biochemsitry from the University of Waterloo and holds a PhD in Molecular Genetics from the University of Toronto.

Bryan leads internal laboratory research and development team. Bryan has 2 decades of experience in research and development for clinical diagnostics, including leading multiple product development teams for both RUO and IVD products. Bryan joined Genece Health from ChromaCode where he was a Sr Staff Scientist leading development teams for their oncology product portfolio. Previously Bryan worked in scientific support and as a scientist at GenMark Diagnostics, a Roche Company, and at BioFire Diagnostics, a BioMerieux Company. Bryan holds a BS in microbiology from Weber State University and an MS in microbiology from Idaho State University.

Greg led the efforts to build the Genece team and establish our partnership with GC Genome to bring their novel early cancer detection technology to the US. Greg has a long track record of developing and commercializing novel molecular diagnostics technologies and instrumentation for clinical labs. Greg was formerly a founder at ChromaCode, taking the company from inception to profitability as it’s CEO. He also guided four-fold revenue growth as the GM of commercial operations at Luminex and previously held commercial leadership roles at Nanogen, Chiron, and BioRad. Greg has a degree in molecular and cellular biology from the University of Colorado Boulder and dual MBA and MHA degrees from the University of Minnesota.

DJ is responsible for establishing a strong internal and external medical engagements for the company. He has expertise in medicine, immunology, and rheumatic disease, having served as a professor at Ajou University School of Medicine for over 25 years. He has also served in several leadership positions including CEO of GC Cell, a cell-based immune cell therapy company in Korea for the last 7 years. DJ received his MD from Yonsei University School of Medicine, his PhD from Korea University School of Medicine, and his MPH from the University of Minnesota School of Public Health.

Jay is a Managing Director in the Strategic Planning Division at GC Holdings, a holding company for GC Corporation, one of the largest biopharmaceutical companies in Korea, with over 6,000 employees. Jay brings over 15 years of professional experience leading both organic and inorganic business development projects with contributions in areas spanning from strategic planning, operations and management system optimization, as well as leading major cross-border M&A deals. Most recently, he played a vital role for launching GC’s cancer diagnostics and therapy businesses in the US and continues to oversee early-stage, innovative technology developments that align with the corporate strategy and vision of GC.

Yong-Jun Huh is the CEO of GC Corporation, South Korea’s leading biopharmaceutical group. Since joining GC in 2003, he circulated through the group and its 29 subsidiaries worldwide in diverse managerial and leadership capacities, including his role as the CEO of GC's wholly-owned Chinese subsidiary in 2008. In his present tenure as the head of the group’s holding company, he is spearheading growth by focusing on overarching global corporate development at both the individual subsidiary and organizational level. Mr. Huh holds a B.Sc. from Yonsei University in Korea and MBA from Wisconsin School of Business.

Dr Gunn, a board certified pathologist, specializes in genomic biomarker identification for the delivery of precision medicine. Dr Gunn’s Boards, Licensures, and Certifications include the American Board of Pathology, Certified in Clinical Pathology, Texas, New York, and California licensure, as well as a New York State Certificate of Qualification in Molecular and Cellular Tumor Markers.

Through her multiple peer-reviewed publications and speaking engagements across the US, Dr Gunn has established a reputation as an expert in the field of molecular pathology. As a prolific writer, Dr Gunn’s research has appeared in numerous scientific publications including Leukemia, Journal of Molecular Diagnostics, and Modern Pathology.

Having received a combined MD, PhD degree from the University of Texas Health Science Center Medical School in San Antonio, Texas, Dr Gunn went on to complete a clinical pathology residency at UT Medical School where she also was an assistant professor in the Department of Pathology. She now serves as Chief Medical Officer for ResearchDx in Irvine, CA.

Byoungsok Jung is the CTO at GC Genome with a focus on early cancer detection. He is also the former Vice President of Research and Development and a founding member at GRAIL where he led efforts to enable early detection using technological innovation in human genomics and machine learning. His team developed cutting edge NGS assays in collaboration with bioinformatics and data scientists. Prior to joining GRAIL, Byoungsok worked on various NGS assay research and development projects at Illumina Research department. Byoungsok holds a BS in Aerospace Engineering from Seoul National University in South Korea, PhD in Mechanical Engineering from Stanford University.

Mark has over 25 years of oncology diagnostics experience, focused on bringing novel products to market to drive precision medicine. His experience includes business development leadership positions at Exact Sciences, Guardant Health, and Epic Sciences developing and launching multiple blood based LDT and IVD products. His career has focused on positioning diagnostics to accelerate pharma drug development and improve patient outcomes.

Dr. Pike is a physician-scientist at Memorial Sloan Kettering Cancer Center who specializes in the management of patients with brain tumors and metastatic disease. He leads a large research group focused on biomarker development for prognostication, treatment selection, and the early detection of cancer, with a particular focus on liquid biopsy. He leads several major studies seeking to train and validate multi-cancer early detection assays. Prior to joining MSK, Dr. Pike completed graduate studies, medical school, and residency training at Oxford University, the Yale School of Medicine, and Harvard University. As a Rhodes Scholar, he studied the adaptive responses of cancer cells to tumor hypoxia.